Access to Bispecific Therapies for Multiple Myeloma: An Overview of Barriers and Emerging Solutions

Bispecific T-cell engagers (TCEs) have transformed the treatment landscape for patients with relapsed/refractory multiple myeloma. However, the benefits of these therapies cannot be fully realized in real-world practice if patients are unable to access them. Poorer survival outcomes among certain patients with multiple myeloma are partly attributed to disparities in access to care driven by multiple barriers, including geographic constraints, socioeconomic, patient-level, and health system-level limitations. These inequities further restrict access to novel treatments, including bispecific T-cell engager therapies. This article provides an overview of the current barriers to accessing bispecific therapies and discusses potential, evidence-based strategies to improve equitable access.